<?xml version="1.0" encoding="UTF-8"?>
<fig id="f2-1030522" position="float">
 <label>Figure 2.</label>
 <caption>
  <p>aGvHD: non-relapse mortality and relapse outcomes. Cumulative incidence of (A) grade II-IV aGvHD*, (B) grade III-IV aGvHD*, (C) non-relapse mortality (NRM), and (D) relapse per treatment arm. Black indicates arm A (tac/mtx), red indicates arm B (bort/tac/mtx), and blue indicates arm C (bort/sir/tac). Grayâ€™s test for comparing the entire distributions was used. *: Acute graft-
   <italic>versus</italic>-host disease (GvHD) after relapse with IS taper included. Tac: tacrolimus; Mtx: methotrexate; Bort: bortezomib; Sir: sirolimus.
  </p>
 </caption>
 <graphic xlink:href="103522.fig2" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
